Skip to Content
Merck
All Photos(2)

Documents

311383

Sigma-Aldrich

Arsenic(III) oxide

ACS reagent (primary standard)

Synonym(s):

Arsenic trioxide, Arsenous acid

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
As2O3
CAS Number:
1327-53-3
Molecular Weight:
197.84
EC Number:
215-481-4
MDL number:
MFCD00003433
UNSPSC Code:
12171602
PubChem Substance ID:
329753664
NACRES:
NB.24

grade

ACS reagent (primary standard)

vapor pressure

0 hPa ( 66 °C)

Assay

99.95-100.05%

form

powder

reaction suitability

reagent type: catalyst
core: arsenic

ign. residue

≤0.02%

solubility

dilute HCl: insoluble ≤0.01%

anion traces

S2-: passes test (lim. ~0.001%)
chloride (Cl-): ≤0.005%

cation traces

Fe: ≤5 ppm
Pb: ≤0.002%
Sb: ≤0.05%

SMILES string

O=[As]O[As]=O

InChI

1S/As2O3/c3-1-5-2-4

InChI key

IKWTVSLWAPBBKU-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Arsenic (III) oxide, also referred to as arsenic trioxide, is an amphoteric oxide that is used as a raw material to produce several arsenic-based compounds.

Application

Arsenic (III) oxide is used
  • In the synthesis of arsenic pentafluoride (AsF5) by static fluorination method in a closed system.
  • In the preparation of arsenic-doped ZnO films by adding As2O3 to zinc acetate, 2-methoxyethanol, and monoethanolamine by sol-gel spin coating method.

Signal Word

Danger

Hazard Statements

H300,H314,H350,H372,H410

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1

Target Organs

Respiratory system,Cardio-vascular system,Gastrointestinal tract

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH SVHC Candidate List

CAS No.

EU REACH Annex XVII (Restriction List)

CAS No.

EU REACH Annex XIV (Authorisation List)

CAS No.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yanfei Jia et al.
PloS one, 8(1), e54774-e54774 (2013-02-06)
Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC), represented by the production of AFP, has a more aggressive behavior than common gastric cancer. The underlying mechanisms are not well understood. Arsenic trioxide (As(2)O(3)) is used clinically to treat acute promyelocytic leukemia(APL) and has
Liangchun Hao et al.
Journal of pediatric hematology/oncology, 35(2), e67-e70 (2013-02-16)
The aim of this study was to investigate the hepatotoxicity induced by arsenic trioxide (As2O3) at a therapeutic dose for pediatric acute promyelocytic leukemia (APL). A total of APL patients received As2O3 treatment by IV drip. Hepatotoxicity was monitored based
Yuhua Fan et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 31(1), 80-91 (2013-02-01)
Arsenic trioxide (As2O3) is a highly effective agent for treatment of acute promyelocytic leukemia (APL). However, consecutively administered As2O3 induces serious adverse cardiac effects, including long QT syndrome (LQTs) and even sudden cardiac death. Previous studies have shown that genistein
Huihui Wang et al.
Environmental toxicology, 28(5), 267-275 (2013-04-17)
Although arsenic is effective in the treatment of acute promyelocytic leukemia (APL), as a well-known environmental toxicant, the side effects of arsenic treatment and arsenic methylation metabolism of the patients are rarely reported. In this manuscript, we investigated 23 APL
Athena Kritharis et al.
Annals of hematology, 92(6), 719-730 (2013-03-16)
For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service